INABHealthcare · BiotechnologyThe 3 Wall Street analysts covering IN8bio, Inc. hold a median 12-month price target of $6 — +328.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 7 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores IN8bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Value (13): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INAB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +328.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $6.00 |
| 14 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2025 | Jones Trading | Upgrade | Buy | — |
| 26 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Aug 2024 | Jones Trading | Downgrade | Hold | — |
| 14 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 June 2024 | Jones Trading | Maintains | Buy | — |
| 4 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2024 | Laidlaw & Co. | Initiates | Buy | — |
| 15 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2024 | JonesTrading | Initiates | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2023 | EF Hutton | Reiterates | Buy | — |
| 16 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INAB appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, IN8bio, Inc. returned −43.1% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 79% of US stocks
Cheaper than 78% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IN8bio, Inc. has a market value of $14.0M and an enterprise value of −$1.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$18.7M.
Free cash flow in the twelve months to 30 June 2026: −$14.6M.
Trailing P/E: −0.3×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
IN8bio, Inc. employs 18 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IN8bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
IN8bio granted one new employee a nonqualified stock option to purchase 60,000 shares. The award was granted under its 2026 Inducement Plan on October 1, 2026, as an inducement to employment under Nasdaq Listing Rule 5635(c)(4).
Why it matters — INAB watchers may note the share-based compensation award and its potential effect on the company’s outstanding equity.
IN8bio announced that CEO William Ho will participate in the Sidoti Small-Cap Virtual Conference held September 23-24, 2026. The clinical-stage biopharmaceutical company develops gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases.
Why it matters — INAB watchers may be interested because the CEO's conference participation provides company exposure to the small-cap investment community without any operational or financial details.
IN8bio announced that CEO and Co-Founder William Ho will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The company is a clinical-stage biopharmaceutical firm developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases.
Why it matters — The CEO's participation provides an opportunity for IN8bio to present its pipeline and strategic direction to investors at a major investment conference.
IN8bio announced the appointment of Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development. Polyakova is a renowned expert in γδ T cells and T cell engagers with two decades of drug discovery and development experience, and will join as the company advances its γδ T cell engager platform.
Why it matters — IN8bio watchers would care because the appointment brings specialized domain expertise in γδ T cells and T cell engagers to strengthen the company's leadership as it advances its novel platform.
The 3 Wall Street analysts covering IN8bio, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering IN8bio, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IN8bio, Inc. 50 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 7 Oct 2026, IN8bio, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +328.6% from the last close, and Ticker Nerd's factor model ranks IN8bio, Inc. 50 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering IN8bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $10 over the next 12 months.
IN8bio, Inc. returned -43.1% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases.
The most recent item we track (GlobeNewsWire, 6 Oct 2026): "IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)". IN8bio granted one new employee a nonqualified stock option to purchase 60,000 shares. The award was granted under its 2026 Inducement Plan on October 1, 2026, as an inducement to employment under Nasdaq Listing Rule 5635(c)(4).
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases. IN8bio’s current pipeline centers on cell-based immunotherapies designed to target solid and hematologic tumors, with programs spanning allogeneic, autologous, iPSC-derived, and genetically modified approaches. Its lead and clinical programs include candidates being studied in glioblastoma and leukemia settings, reflecting the company’s emphasis on difficult-to-treat cancers and unmet medical needs. IN8bio also advances a T cell engager platform intended to broaden the reach of its immunotherapy portfolio across oncology and autoimmune indications. Based in New York, IN8bio plays a niche role in the biotechnology market as a developer of next-generation cellular medicines.
CEO Mr. Tai-Wei Ho · 18 employees · United States · https://in8bio.com
